Role of Antioxidants in Mitigating Oxidative Degradation
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Accelerated studies expose drug products to higher-than-normal temperature and humidity (commonly 40°C ± 2°C / 75% RH ± 5%) to accelerate degradation processes. The goal is to identify potential instability, degradation pathways, and estimate product shelf life over a shorter timeframe compared to real-time studies.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Kinetic modeling involves applying mathematical equations to describe how a drug product degrades over time. The most common models are based on zero-order or first-order reaction kinetics, which correlate concentration changes of the active pharmaceutical ingredient (API) to time under various temperature conditions.
Click to read the full article.
According to ICH Q1A(R2), intermediate conditions are required:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Real-time stability studies involve storing pharmaceutical products under recommended long-term storage conditions (e.g., 25°C ± 2°C / 60% RH ± 5%) and testing them at predetermined intervals throughout the proposed shelf life. The goal is to demonstrate that the drug product maintains its quality over its entire intended lifecycle.
Click to read the full article.
